Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Andrew Baum's Stock Ratings
Citigroup Analyst
Andrew Baum is an analyst at Citigroup. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/04/2025
Overall Average Return
12.8%
Smart Score
Overall Average Return Percentile
70th
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 02/05/2025 | MRK | Buy Now | Merck & Co | $83.28 | 38.09% | Andrew Baum71% | $125 → $115 | Maintains | Buy | Get Alert |
| 01/28/2025 | PFE | Buy Now | Pfizer | $24.18 | 19.93% | Andrew Baum71% | $30 → $29 | Maintains | Neutral | Get Alert |
| 01/28/2025 | MRK | Buy Now | Merck & Co | $83.28 | 50.1% | Andrew Baum71% | $130 → $125 | Maintains | Buy | Get Alert |
| 01/28/2025 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 28.26% | Andrew Baum71% | $60 → $65 | Maintains | Neutral | Get Alert |
| 11/12/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 18.39% | Andrew Baum71% | $55 → $60 | Maintains | Neutral | Get Alert |
| 10/25/2024 | RPRX | Buy Now | Royalty Pharma | $32.99 | 21.25% | Andrew Baum71% | $60 → $40 | Maintains | Buy | Get Alert |
| 10/25/2024 | MRK | Buy Now | Merck & Co | $83.28 | 56.1% | Andrew Baum71% | $140 → $130 | Maintains | Buy | Get Alert |
| 10/25/2024 | ABBV | Buy Now | AbbVie | $199.03 | 8.02% | Andrew Baum71% | $170 → $215 | Maintains | Buy | Get Alert |
| 10/25/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 8.52% | Andrew Baum71% | $75 → $55 | Downgrade | Buy → Neutral | Get Alert |
| 04/02/2024 | LLY | Buy Now | Eli Lilly and Co | $825.00 | 8.48% | Andrew Baum71% | $675 → $895 | Maintains | Buy | Get Alert |
| 10/23/2023 | LLY | Buy Now | Eli Lilly | $825.00 | -18.18% | Andrew Baum71% | $525 → $675 | Maintains | Buy | Get Alert |
| 10/20/2023 | ALVO | Buy Now | Alvotech | $8.22 | 21.65% | Andrew Baum71% | $5 → $10 | Upgrade | Sell → Neutral | Get Alert |
| 10/16/2023 | PFE | Buy Now | Pfizer | $24.18 | 44.75% | Andrew Baum71% | $42 → $35 | Maintains | Neutral | Get Alert |
| 07/26/2023 | LLY | Buy Now | Eli Lilly | $825.00 | -36.36% | Andrew Baum71% | $360 → $525 | Maintains | Buy | Get Alert |
| 04/13/2023 | MRK | Buy Now | Merck & Co | $83.28 | 56.1% | Andrew Baum71% | $105 → $130 | Upgrade | Neutral → Buy | Get Alert |
| 03/03/2023 | LLY | Buy Now | Eli Lilly | $825.00 | -56.36% | Andrew Baum71% | $370 → $360 | Maintains | Buy | Get Alert |
| 09/06/2022 | ALVO | Buy Now | Alvotech | $8.22 | -39.17% | Andrew Baum71% | $12 → $5 | Downgrade | Buy → Sell | Get Alert |
| 07/26/2022 | ALVO | Buy Now | Alvotech | $8.22 | 45.99% | Andrew Baum71% | → $12 | Initiates | → Buy | Get Alert |
| 05/26/2022 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 77.58% | Andrew Baum71% | $75 → $90 | Maintains | Buy | Get Alert |
| 04/05/2022 | PFE | Buy Now | Pfizer | $24.18 | 135.73% | Andrew Baum71% | $46 → $57 | Maintains | Neutral | Get Alert |
| 03/01/2022 | ABBV | Buy Now | AbbVie | $199.03 | -14.59% | Andrew Baum71% | $155 → $170 | Reiterates | Buy → Buy | Get Alert |
| 01/27/2022 | ABBV | Buy Now | AbbVie | $199.03 | -22.12% | Andrew Baum71% | $125 → $155 | Maintains | Buy | Get Alert |
| 11/29/2021 | MRK | Buy Now | Merck & Co | $83.28 | 2.07% | Andrew Baum71% | $105 → $85 | Downgrade | Buy → Neutral | Get Alert |
| 10/29/2021 | RPRX | Buy Now | Royalty Pharma | $32.99 | 51.56% | Andrew Baum71% | → $50 | Upgrade | Neutral → Buy | Get Alert |
| 09/29/2021 | LLY | Buy Now | Eli Lilly | $825.00 | -67.88% | Andrew Baum71% | $210 → $265 | Upgrade | Neutral → Buy | Get Alert |
| 03/12/2021 | ABBV | Buy Now | AbbVie | $199.03 | -37.2% | Andrew Baum71% | $105 → $125 | Maintains | Buy | Get Alert |
| 09/02/2020 | ABBV | Buy Now | AbbVie | $199.03 | -47.24% | Andrew Baum71% | $98 → $105 | Maintains | Buy | Get Alert |
| 01/06/2020 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 44.04% | Andrew Baum71% | → $73 | Reinstates | → Buy | Get Alert |
| 11/20/2019 | ABBV | Buy Now | AbbVie | $199.03 | -50.76% | Andrew Baum71% | $90 → $98 | Maintains | Buy | Get Alert |
| 09/26/2019 | ABBV | Buy Now | AbbVie | $199.03 | — | Andrew Baum71% | — | Upgrade | Neutral → Buy | Get Alert |
| 11/26/2018 | LLY | Buy Now | Eli Lilly | $825.00 | — | Andrew Baum71% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/06/2018 | PFE | Buy Now | Pfizer | $24.18 | 53.02% | Andrew Baum71% | $34 → $37 | Maintains | Sell | Get Alert |
| 11/01/2018 | MRK | Buy Now | Merck & Co | $83.28 | 0.86% | Andrew Baum71% | $79 → $84 | Maintains | Buy | Get Alert |
| 10/31/2018 | MRK | Buy Now | Merck & Co | $83.28 | 0.86% | Andrew Baum71% | $79 → $84 | Maintains | Buy | Get Alert |
| 10/22/2018 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 12.47% | Andrew Baum71% | $62 → $57 | Downgrade | Buy → Neutral | Get Alert |
| 10/16/2018 | MRK | Buy Now | Merck & Co | $83.28 | -5.14% | Andrew Baum71% | $70 → $79 | Maintains | Buy | Get Alert |
| 10/18/2017 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 42.07% | Andrew Baum71% | $55 → $72 | Maintains | Buy | Get Alert |
| 10/18/2017 | MRK | Buy Now | Merck & Co | $83.28 | — | Andrew Baum71% | — | Upgrade | Neutral → Buy | Get Alert |
| 07/05/2017 | GSK | Buy Now | GSK | $39.07 | — | Andrew Baum71% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/16/2017 | PFE | Buy Now | Pfizer | $24.18 | — | Andrew Baum71% | — | Downgrade | Neutral → Sell | Get Alert |
| 11/28/2016 | ABBV | Buy Now | AbbVie | $199.03 | — | Andrew Baum71% | — | Downgrade | Buy → Neutral | Get Alert |
| 09/20/2016 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 38.12% | Andrew Baum71% | $75 → $70 | Maintains | Buy | Get Alert |
| 08/08/2016 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 47.99% | Andrew Baum71% | $80 → $75 | Maintains | Buy | Get Alert |
| 02/23/2016 | ABBV | Buy Now | AbbVie | $199.03 | -67.34% | Andrew Baum71% | $56 → $65 | Upgrade | Neutral → Buy | Get Alert |
| 09/28/2015 | ABBV | Buy Now | AbbVie | $199.03 | -69.85% | Andrew Baum71% | $55 → $60 | Upgrade | — | Get Alert |
| 04/29/2015 | LLY | Buy Now | Eli Lilly | $825.00 | — | Andrew Baum71% | — | Upgrade | Neutral → Buy | Get Alert |
| 02/09/2015 | PFE | Buy Now | Pfizer | $24.18 | 53.02% | Andrew Baum71% | $36 → $37 | Maintains | Buy | Get Alert |
| 02/09/2015 | ABBV | Buy Now | AbbVie | $199.03 | -75.88% | Andrew Baum71% | → $48 | Initiates | → Sell | Get Alert |
| 07/31/2014 | LLY | Buy Now | Eli Lilly | $825.00 | -92% | Andrew Baum71% | $60 → $66 | Downgrade | Buy → Neutral | Get Alert |
| 07/08/2014 | MRK | Buy Now | Merck & Co | $83.28 | -31.56% | Andrew Baum71% | $44 → $57 | Maintains | Neutral | Get Alert |
| 07/07/2014 | MRK | Buy Now | Merck & Co | $83.28 | -31.56% | Andrew Baum71% | $44 → $57 | Maintains | Neutral | Get Alert |
| 04/29/2014 | PFE | Buy Now | Pfizer | $24.18 | 48.88% | Andrew Baum71% | $31 → $36 | Maintains | Buy | Get Alert |
| 08/06/2013 | GSK | Buy Now | GSK | $39.07 | — | Andrew Baum71% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/22/2013 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | 8.52% | Andrew Baum71% | $33 → $55 | Upgrade | Neutral → Buy | Get Alert |
| 01/30/2013 | LLY | Buy Now | Eli Lilly | $825.00 | -92.73% | Andrew Baum71% | $55 → $60 | Maintains | Buy | Get Alert |
| 11/30/2012 | PFE | Buy Now | Pfizer | $24.18 | 19.93% | Andrew Baum71% | → $29 | Initiates | → Buy | Get Alert |
| 11/30/2012 | MRK | Buy Now | Merck & Co | $83.28 | -47.17% | Andrew Baum71% | → $44 | Initiates | → Neutral | Get Alert |
| 11/30/2012 | LLY | Buy Now | Eli Lilly | $825.00 | -93.33% | Andrew Baum71% | → $55 | Initiates | → Buy | Get Alert |
| 11/29/2012 | LLY | Buy Now | Eli Lilly | $825.00 | -93.33% | Andrew Baum71% | → $55 | Maintains | Buy | Get Alert |
| 11/29/2012 | BMY | Buy Now | Bristol-Myers Squibb | $50.68 | -34.89% | Andrew Baum71% | → $33 | Initiates | → Neutral | Get Alert |
| 11/29/2012 | PFE | Buy Now | Pfizer | $24.18 | 19.93% | Andrew Baum71% | → $29 | Maintains | Buy | Get Alert |
| 07/12/2012 | MRK | Buy Now | Merck & Co | $83.28 | -39.96% | Andrew Baum71% | $34 → $50 | Upgrade | Neutral → Buy | Get Alert |
| 04/02/2012 | PFE | Buy Now | Pfizer | $24.18 | -4.88% | Andrew Baum71% | $19 → $23 | Maintains | Neutral | Get Alert |
